Anti-Cardiolipin IgG/IgM ELISA (96 wells) Cat 023-001
Anti-Cardiolipin IgG/IgM ELISA (288 wells) Cat 023-002

Measures IgG and/or IgM anti-cardiolipin antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population.

Anti-Cardiolipin IgA ELISA (96 wells) Cat 026-001
Anti-Cardiolipin IgA ELISA (288 wells) Cat 026-006

Measures IgA anti-cardiolipin antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population.

Anti-Phosphatidylserine IgG/IgM ELISA (96 wells) Cat 030-001
Anti-Phosphatidylserine IgG/IgM ELISA (288 wells) Cat 030-002

Measures IgG and/or IgM anti-phosphatidylserine antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population. Phosphatidylserine, a platelet and endothelial cell membrane lipid, participates in the coagulation cascade making it a more relevant antigen for use in anti-phospholipid testing.

Anti-Phosphatidylserine IgA ELISA (96 wells) Cat 10206
Anti-Phosphatidylserine IgA ELISA (288 wells) Cat 10497

Measures IgA anti-phoshphatidylserine antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population. Phosphatidylserine, a platelet and endothelial cell membrane lipid, participates in the coagulation cascade making it a more relevant antigen for use in anti-phospholipid testing.

Anti-Beta 2 Glycoprotein I IgG ELISA (96 wells) Cat 037-001

Measures IgG anti-beta 2 glycoprotein I antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population. Antibodies recognising beta 2 glycoprotein I, a natural anticoagulant which serves as a necessary cofactor for most anti-phospholipid binding, are reported to be a more specific marker for thrombosis than antibodies detected by classic antiphospholipid ELISAs (anti-cardiolipin, anti-phosphatidylserine).

Anti-Beta 2 Glycoprotein I IgM ELISA (96 wells) Cat 038-001

Measures IgM anti-beta 2 glycoprotein I antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population. Antibodies recognising beta 2 glycoprotein I, a natural anticoagulant which serves as a necessary cofactor for most anti-phospholipid binding, are reported to be a more specific marker for thrombosis than antibodies detected by classic antiphospholipid ELISAs (anti-cardiolipin, anti-phosphatidylserine).

Anti-Beta 2 Glycoprotein I IgA ELISA (96 wells) Cat 039-001

Measures IgA anti-beta 2 glycoprotein I antibody levels for use in the diagnosis of anti-phospholipid syndrome and the risk assessment of increased blood clotting (thrombosis) in the general population. Antibodies recognising beta 2 glycoprotein I, a natural anticoagulant which serves as a necessary cofactor for most anti-phospholipid binding, are reported to be a more specific marker for thrombosis than antibodies detected by classic antiphospholipid ELISAs (anti-cardiolipin, anti-phosphatidylserine).

Anti-Prothrombin Antibody IgG ELISA (96 wells) Cat 10238

An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative determination of IgG anti-prothrombin (aPT) antibodies in human serum or citrated plasma (3.2% sodium citrate). For the detection and semi-quantitation of IgG anti-prothrombin (aPT) antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (e.g., antiphospholipid syndrome).

Anti-Prothrombin Antibody IgM ELISA (96 wells) Cat 10240

An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative determination of IgM anti-prothrombin (aPT) antibodies in human serum or citrated plasma (3.2% sodium citrate). For the detection and semi-quantitation of IgM anti-prothrombin (aPT) antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (e.g., antiphospholipid syndrome).